Evidence that endogenous c-MYC could act as an oncogene came from the discovery of chromosomal translocations between chromosomes 8 and 14 in Burkitt's lymphoma that placed the c-MYC gene adjacent to immunoglobulin heavy chain (IgH) transcriptional enhancer sequences, resulting in elevated c-MYC transcription and increased protein levels (Dalla-Favera et al., 1982; Neel et al., 1982; Taub et al., 1982). Here, MYC is linked to Burkitt lymphoma.